ERBB3 and hepatocellular carcinoma: Similarly, hepatoma cells are able to overcome IGF1R inhibition through HER3 activation in an EGFR-dependent mechanism, suggesting HER3 is an important mediator in acquired resistance to anti-IGF1R therapy [77].